Skip to main content
. 2020 Jul 10;26(10):5766–5788. doi: 10.1038/s41380-020-0806-5

Table 1.

List of participant donors of cells for iPSC-organoid generation and reproducibility of AD-like pathology (by histological analysis).

Participant DS Age at sample collection Sex Dementia status APOE Donated primary material Number of iPSC clones generated Number of clones used for organoid generation Number of organoids with AD-like-pathology/total number of histologically analysed organoids
QM-DS1 Yes 40 F Diagnosed at 40, symptoms at 37 3,3 Hair strands 3 2 9/9 (two iPSC clones analysed)
QM-DS2 Yes 67 M Diagnosed at 63 3,3 Hair strands 5 1 12/12
QM-DS3 Yes 38 M Diagnosed at 37 3,4 Hair strands 1 1 7/7
QM-DS4 Yes 64 M Diagnosed at 62 (brother and sister have AD) 3,3 Hair strands 3 2 6/6 (two iPSC clones analysed)
QM-DS5 Yes 60 M Diagnosed at 62 3,3 Hair strands 3 2 6/6 (two iPSC clones analysed)
QM-DS6 Yes 31 F No dementia at 37 3,4 Hair strands 8 2 0/6 (two iPSC clones analysed)
QM-DupAPP No 64 M FEOAD, no DS 3,3 Blood sample 2 2 5/5 (two iPSC clones analysed)
D21C3 (isogenic) D21 normal karyotype from DS mosaic 16 F Unknown 3,4 Skin biopsy 3 3 0/10 (three iPSC clones analysed)
D21C9 (isogenic)
D21C7 (isogenic)
T21C6 (isogenic) T21 karyotype from DS mosaic 3 3 0/23 (three iPSC clones analysed)
T21C13 (isogenic)
T21C5 (isogenic)
T21C5Δ7 (isogenic CRISPR BACE2) T21 karyotype from DS mosaic (disomy BACE2 by CRISPR) 1 1 18/18
T21C5Δ7 (isogenic CRISPR BACE2) + DMSO 3/3
T21C5Δ7 (isogenic CRISPR BACE2)+ β and γ sec inhibitors 0/4